It is generally assumed that recurrent mutations within a given cancer driver gene elicit similar drug responses. Cancer genome studies have identified recurrent but divergent missense mutations affecting the substrate-recognition domain of the ubiquitin ligase adaptor SPOP in endometrial and prostate cancers. The therapeutic implications of these mutations remain incompletely understood. Here we analyzed changes in the ubiquitin landscape induced by endometrial cancer-associated SPOP mutations and identified BRD2, BRD3 and BRD4 proteins (BETs) as SPOP-CUL3 substrates that are preferentially degraded by endometrial cancer-associated SPOP mutants. The resulting reduction of BET protein levels sensitized cancer cells to BET inhibitors. Conversely, prostate cancer-specific SPOP mutations resulted in impaired degradation of BETs, promoting their resistance to pharmacologic inhibition. These results uncover an oncogenomics paradox, whereby mutations mapping to the same domain evoke opposing drug susceptibilities. Specifically, we provide a molecular rationale for the use of BET inhibitors to treat patients with endometrial but not prostate cancer who harbor SPOP mutations. nAture medicine VOLUME 23 | NUMBER 9 | SEPTEMBER 2017 1 0 4 7
Specific mutations in cancer-related genes can indicate whether a patient with cancer may or may not respond to a given drug 1 . Generally, it is assumed that recurrent mutations within a specific gene have similar therapeutic implications, especially if the resulting amino acid changes occur within the same protein-coding domain. Genome studies have revealed recurrent point mutations mapping to the substrate-recognition domain of the ubiquitin ligase adaptor speckle-type POZ protein (SPOP) in 4-14% of prostate and endometrial cancers (Fig. 1a) [2] [3] [4] [5] [6] . In prostate cancer, SPOP mutations are confined to the amino acid residues of the substrate-binding cleft-a specific region within the substrate-recognition domain that is essential for substrate interaction and ubiquitin transfer 7 . We and others have subsequently shown that these mutations act in a dominant-negative fashion to repress ubiquitination and degradation of oncogenic substrate proteins [8] [9] [10] [11] [12] . In contrast, recurrent amino acid substitutions in endometrial cancer and carcinosarcoma occur in an uncharacterized portion of the substrate-recognition domain ( Fig. 1a and Supplementary Fig. 1a ) [4] [5] [6] . Given the divergent mutation patterns in these tumor types, we speculated that SPOP mutations associated with endometrial cancer might differentially affect protein ubiquitination in comparison to prostate cancer-specific SPOP mutations, possibly resulting in distinct therapeutic opportunities.
RESULTS
Cancer-type-specific SPOP mutations have opposing effects on BET protein levels To explore this hypothesis, we characterized changes in the ubiquitination landscape specific to endometrial cancer-associated SPOP mutants by mass spectrometry-based proteomics. To ensure that disease-relevant proteins were being expressed in our experimental setting, we chose human Ishikawa endometrial cancer cells, derived from a well-differentiated endometrioid cancer, for experimentation because their robustly expressed genes substantially overlapped with those found in SPOP-mutant tumor tissues ( Supplementary Fig. 1b) 6, 13 . Subsequently, we generated cells that stably overexpressed control vector, wild-type SPOP (SPOP-WT) or one of seven endometrial cancer-specific mutated SPOP variants (E47K, E50K, E78K, S80R, M117V, R121Q and D140N; SPOP-MTs) ( Supplementary Fig. 1c ). In each case, we measured glycine-glycine remnants of ubiquitinated lysines (K-ε-GG) after trypsin digestion and stable isotope labeling of amino acids in cell culture (SILAC)-based mass spectrometry ( Supplementary  Fig. 1d ) 14 . All K-ε-GG values (n = 17,239), defined as ratios of mutant to SPOP-WT, were normalized to the corresponding protein ratios to account for ubiquitination-related changes in protein levels ( Supplementary Table 1 ). K-ε-GG peptide values for cells expressing individual SPOP-MTs were compared to those from cells overexpressing SPOP-WT within experiments (Supplementary Fig. 2a,c,e,g) .
Because protein ubiquitination is often linked to proteasomal degradation, we asked which differentially expressed K-ε-GG peptides showed an inverse correlation with protein abundance ( Supplementary Table 1 and Supplementary Fig. 2b,d,f,h) . We identified two patterns of ubiquitination and protein dysregulation in known and putative SPOP substrates pointing to possible private contact points between individual substrates and the mutant meprin and TRAF homology (MATH) domain (Fig. 1b,c and Supplementary Figs. 2 and 3a) . Peptides corresponding to tripartite-motif-containing 24 (TRIM24), anterior gradient protein 2 homolog (AGR-2) and nuclear receptor coactivator 3 (NCOA3)-all proteins with reported oncogenic properties-showed a decrease in K-ε-GG peptide abundance in cells expressing SPOP-MTs, followed by an increase in levels of the corresponding protein 9, 15, 16 . Similar dominant-negative patterns of substrate dysregulation by prostate cancer-specific SPOP mutants have been reported for TRIM24 and NCOA3 (refs. 8, 9, 17) . Recurrently mutated amino acid residues in prostate cancer are highlighted in blue and those in endometrial cancer are in red 7 . The substrate-binding cleft is shown in green. (b) Scatterplot showing expression differences for the indicated proteins in Ishikawa endometrial cancer cells expressing SPOP mutants (SPOP-MTs) versus wild-type SPOP (SPOP-WT). Dashed red lines, ±2 s.d. (c) Representative western blot validation for the indicated proteins in Ishikawa cells stably expressing vector control, SPOP-WT or an endometrial cancer-specific SPOP mutant (n = 5). (d) Representative western blot for the indicated proteins in Ishikawa endometrial cancer cells expressing prostate cancer-specific SPOP mutants (n = 3). (e) Representative western blot for the indicated proteins in 22Rv1 prostate cancer cells stably expressing prostate cancer-associated SPOP mutants (n = 3). In b-d, β-actin (ACTB) is used as a loading control. (f) Left, representative images of primary human endometrial cancer tissues stained for BRD2, BRD3 and BRD4 by immunohistochemistry (IHC) ( Supplementary Fig. 4c,d) ; right, corresponding quantification of protein expression levels in primary tumors stratified according to SPOP mutation status. Scale bars, 20 µm. (g) Analysis of BRD2, BRD3 and BRD4 expression in primary human prostate cancer tissues stratified according to SPOP mutation status ( Supplementary Fig. 4g ). R correlation coefficients and P values were derived from Kendall's tau-b. In each panel, n indicates the number of independent experiments performed.
The most striking changes were found in proteins that exhibited robust upregulation of K-ε-GG peptides coupled with downregulation of the corresponding protein (Fig. 1b,c and Supplementary Figs. 2  and 3a) , including DEK, another characterized SPOP substrate 8 . Yet, the most profound changes at the protein level without concurrent changes at the mRNA level were found in BRD3, BRD2 and BRD4 (Fig. 1b,c and Supplementary Fig. 3b ). These bromodomain and extraterminal (BET)-motif-containing proteins, which serve as promising targets for cancer therapy 18 , may be increasingly ubiquitinated and degraded by endometrial cancer-specific SPOP mutants. Notably, similar changes were also found in human HEC-151 and RL95-2 endometrial cancer cells and in human 22Rv1 prostate cancer cells ( Supplementary Fig. 3c-e ).
Because prostate cancer-specific SPOP mutants have been found to impair ubiquitination of substrates in a dominant-negative manner, we speculated that these mutants might have the opposite effect on BET protein levels of those identified in endometrial cancer [8] [9] [10] [11] . Indeed, overexpression of recurrent prostate cancer-specific mutants increased BET protein levels in human Ishikawa endometrial cancer cells, human 22Rv1 prostate cancer cells, human LHMAR prostate epithelial cells 8 (Fig. 1d,e and Supplementary Fig. 3f-h ) and in mouse prostate epithelial cells 19 . In aggregate, our findings suggest that BET proteins might represent SPOP substrates that are differentially ubiquitinated and degraded by endometrial cancer-and prostate cancer-specific mutants irrespective of cellular lineage. In support of these findings, nuclear levels of BET proteins correlated inversely with recurrent SPOP mutations in human primary endometrial cancer tissues analyzed by immunohistochemistry, whereas a positive correlation was noted in primary human prostate cancer tissues ( Fig. 1f,g and Supplementary Fig. 4 ).
BET proteins are bona fide SPOP substrates
We sought to determine whether SPOP directly interacts with BET proteins to promote ubiquitination. In agreement with this hypothesis, the primary amino acid sequences of the BET proteins contain a conserved consensus sequence that is a SPOP-binding motif ( Fig. 2a) 7 . We focused on BRD3 for experimental follow-up because it was the most differentially regulated BET family member ( Fig. 1b) . First, we overexpressed HA-tagged BRD3 (HA-BRD3) harboring three threonine-to-alanine substitutions at the binding motif (degron-MT) in Ishikawa cells (Supplementary Fig. 5a ) and assessed the ability of SPOP-WT to mediate BRD3 degradation. The substitutions in the degron variant abolished the repressive effect of SPOP and resulted in elevated levels of BRD3 protein relative to those of controls, in agreement with the notion that endogenous SPOP was not able to degrade the degron variant ( Fig. 2b and Supplementary Fig. 5b ). To determine whether the motif mediated direct binding of SPOP to BRD3, we performed immunoprecipitation experiments in cells expressing either wild-type HA-BRD3 or the degron variant. SPOP protein was detectable after immunoprecipitation of wild-type HA-BRD3, whereas the substitutions in the BRD3 degron variant disrupted the BRD3-SPOP interaction ( Fig. 2c) . Thus, the SPOP-binding motif within BRD3 appears to be necessary for SPOP binding.
Next, we tested whether SPOP could ubiquitinate BRD3 as part of a cullin-3 (CUL3)-RING-box protein 1 (RBX1) ubiquitin E3 ligase complex 20 . Knockdown of CUL3 increased HA-BRD3 levels and decreased BRD3 ubiquitination relative to control in 293T cells ( Supplementary Fig. 5c ). Furthermore, SPOP-WT, along with RBX1 and CUL3, directly ubiquitinated wild-type HA-BRD3 in vivo and in vitro, whereas the degron variant of HA-BRD3 remained unaffected ( Fig. 2d and Supplementary Fig. 5d ). Additional CUL3-dependent substrate adaptors (kelch-like family member 9 (KLHL9), KLHL13, KLHL21) failed to ubiquitinate BRD3 in vitro, verifying the specificity of SPOP toward BRD3 (Supplementary Fig. 5d ).
To determine whether BRD3 ubiquitination induces its proteasomal degradation, we cultured SPOP-and BRD3-expressing 293T cells in the presence or absence of the proteasome inhibitor MG132. Shortterm MG132 treatment increased levels of ubiquitinated HA-BRD3 ( Fig. 2d ). Prolonged proteasomal inhibition increased HA-BRD3 and endogenous BET protein levels in the presence of SPOP-WT overexpression ( Fig. 2e and Supplementary Fig. 5e ). SPOP was also detectable after immunoprecipitation of endogenous BET proteins ( Supplementary Fig. 5f ). Moreover, SPOP knockdown increased BET protein levels without concomitant changes in mRNA levels and impaired protein degradation after inhibition of protein synthesis with cycloheximide ( Fig. 2f and Supplementary Fig. 5g,h) . In aggregate, these data are consistent with a model in which ubiquitination of BET proteins promotes their proteasomal degradation.
Cancer-type-specific SPOP mutants induce differential ubiquitination of BET proteins To test whether the functional properties of endometrial cancerspecific SPOP mutants may translate into reduced BET protein levels in comparison to SPOP-WT when these mutants are expressed at endogenous levels, we identified the human EN endometrial cancer cell line that harbors a recurrent SPOP mutation (p.R121Q) in the Cancer Cell Line Encyclopedia (CCLE) (Supplementary Fig. 6a ). We compared BET protein levels in EN cells to those in Ishikawa cells expressing equivalent levels of SPOP-WT ( Fig. 3a) . We found that EN cancer cells exhibited lower levels of BET proteins despite having higher levels of the corresponding mRNAs ( Fig. 3a and Supplementary  Fig. 6b ). In line with the notion that enhanced protein degradation by SPOP-R121Q leads to reduced BET protein levels in EN cells, we found more significant increases in BET protein levels upon SPOP depletion or short-term proteasome inhibition in EN cells than in Ishikawa cells ( Fig. 3b and Supplementary Fig. 6c-e ). In addition to and in accordance with our observations above, endogenous SPOP-R121Q bound more efficiently to BET proteins in EN cells, in which we noted more pronounced degradation of BET proteins after inhibition of protein synthesis with cycloheximide ( Fig. 3c and Supplementary Fig. 6f,g) . Of note, endogenous SPOP levels were also increased after prolonged proteasome inhibition and reduced after inhibition of protein synthesis, indicating proteasomal turnover of SPOP itself ( Figs. 2e and 3b,c) .
To test whether the different BET protein binding and degradation kinetics in human EN and Ishikawa cells were a result of the specific amino acid substitutions within SPOP, we analyzed the activity of different SPOP species side by side in 293T cells. Endometrial cancer-associated SPOP mutants (E50K and R121Q) bound more strongly to HA-BRD3 than SPOP-WT did in vivo and in vitro, whereas the interaction of the prostate cancer-specific SPOP mutants W131G and F133L was reduced ( Fig. 3d and Supplementary  Fig. 6h ). In line with this observation, ubiquitination of HA-BRD3 was increased with the endometrial cancer-specific SPOP mutants and decreased with the prostate cancer-specific mutants ( Fig. 3e and Supplementary Fig. 6i ). We next investigated whether the increase in ubiquitination mediated by the endometrial cancerspecific SPOP mutants was dependent on an intact degron on BRD3. Indeed, SPOP-E50K failed to ubiquitinate the degron variant of BRD3 ( Fig. 3f ) and to reduce BRD3 protein levels ( Supplementary  Fig. 6j ). These results suggest that BET protein levels are at least in part affected by differential interactions between SPOP mutants and the BET degron.
Sensitivity to BET inhibitors is altered by cancer-type-specific SPOP mutations Some cancer cells depend on the presence of BET proteins for tumor growth and survival 18, 21 . Therefore, we sought to determine whether enhanced degradation of BET proteins in the context of endometrial cancer-specific SPOP mutants might create specific vulnerabilities; we speculated that endometrial cancer cells with low BET protein levels might become particularly susceptible to further reduction of BET protein levels. Indeed, EN cells were susceptible to individual knockdown of the BET proteins, which resulted in decreased growth (Supplementary Fig. 7a ). In contrast, to achieve a similar effect on growth in Ishikawa cells, individual BET proteins had to be knocked down in the context of the SPOP-R121Q mutant. These data suggest that endometrial cancer cells with low levels of BET proteins in the context of endometrial cancer-specific SPOP mutants are particularly susceptible to further suppression of BET protein function.
In support of this view, a functional overlap among BET proteins has been reported 22 . BET inhibitors are under clinical investigation as anticancer therapeutics, including for solid tumors 18, 21, 23, 24 . We anticipated that the susceptibility of cancer cells to these inhibitors might be influenced by differences in BET protein levels corresponding to SPOP mutants. Indeed, forced expression of endometrial cancer-specific SPOP mutants (shown to lower BET protein levels) sensitized Ishikawa cells to both BET inhibitors, JQ1 and OTX015, by promoting apoptosis and reducing cellular proliferation ( Fig. 4a and Supplementary Fig. 7b-e) 25, 26 . Similar results were found in HEC-151 and RL95-2 endometrial cancer cells (Supplementary Fig. 7f) . We aimed to discover whether changes in BET protein levels contribute to sensitivity to JQ1. To this end, we found that reduced levels of individual BET proteins in response to expression of SPOP mutants in Ishikawa cells correlated with a decrease in the half-maximal inhibitory concentration (IC 50 ) during JQ1 treatment (Fig. 4b) . Functionally, overexpression of the BRD2, BRD3 and BRD4 degron variants reduced SPOP-E50Kmediated sensitization to JQ1 ( Fig. 4c and Supplementary Fig. 7g ). We then investigated whether increased BET protein levels in the context of prostate cancer might, on the contrary, induce resistance to BET inhibitors. Overexpression of prostate cancer-specific SPOP mutants in comparison to SPOP-WT rendered Ishikawa and 22Rv1 cells more resistant to JQ1 ( Fig. 4a and Supplementary Fig. 7h,i) , whereas individual ( Fig. 4d and Supplementary Fig. 7j,l) or combined ( Supplementary Fig. 7k ) knockdown of BET proteins in the context of mutated SPOP-Y87C dampened this phenotype.
Next, we sought to determine whether recurrent SPOP mutations or decreased BET protein levels in general might predict sensitivity to pharmacologic BET inhibition across cell line models of human endometrial cancer. For this purpose, we assessed JQ1 sensitivity in 3D semisolid culture conditions across 12 different human cell lines, for which we determined BET protein levels in parallel. Decreased expression levels of BRD2, BRD3 and BRD4 were associated with sensitivity to JQ1 in many cases (Supplementary Fig. 8a-c) ; however, we also found some notable exceptions to this rule, in agreement with the existence of other molecular mechanisms that regulate susceptibility to BET inhibitors 27, 28 . Nevertheless, EN cells expressing the SPOP-R121Q mutant were sensitive to JQ1 inhibition, in line with our data generated in isogenic cell lines (Fig. 4a,e and Supplementary  Figs. 7f and 8b) . This finding led us to search for additional cell lines with recurrent endometrial cancer-associated SPOP mutations at the endogenous locus. We identified colorectal (NCI-H508) and urothelial (VM-CUB1) cancer cell lines in the Catalogue of Somatic Mutations in Cancer (COSMIC) Cell Lines Project that harbored SPOP mutations encoding p.E47K and p.E50K, respectively. Both cell lines were particularly sensitive to JQ1 and displayed low BET protein levels that were responsive to proteasomal inhibition ( Fig. 4e and Supplementary  Fig. 8d) . Thus, endometrial cancer-associated SPOP mutations may be more broadly associated with sensitivity to BET inhibitors.
Moreover, we tested whether established SPOP substrates might either directly or indirectly influence responses to JQ1 through changes in BET protein levels. Neither knockdown nor overexpression of DEK, TRIM24, NCOA3 or ERG led to substantial changes in BET protein levels or the JQ1 response, further supporting the notion that SPOP mutants affect sensitivity to JQ1 directly through regulation of BET protein degradation (Supplementary Fig. 9 ).
Transcriptome analysis identifies FOSL1 as a determinant of JQ1 response
BET inhibitors bind to the bromodomains of BET proteins to displace them from the acetylated histone tails of transcriptionally active sites. Considering this function, we investigated transcriptional changes in response to overexpression of SPOP-WT or two recurrent endometrial cancer-and prostate cancer-associated SPOP mutants in Ishikawa cells (Supplementary Table 2) . Unsupervised clustering and multidimensional scaling (MDS) analyses of gene expression revealed mainly opposing transcriptional changes in response to expression of the endometrial cancer-and prostate cancer-associated SPOP mutants, with SPOP-WT positioned in between the different types of SPOP mutants (Supplementary Fig. 10a,b) . This result aligns well with the different BET protein levels observed across the cell lines (Supplementary Fig. 3f) . Interestingly, the MDS analysis revealed a second feature that discriminated both types of mutants from SPOP-WT, possibly reflecting shared dysregulation of SPOP substrates such as TRIM24 or NCOA3 ( Fig. 1c and Supplementary Fig. 10b) 8 .
Next, we interrogated transcriptional changes under JQ1 treatment in cells overexpressing endometrial cancer-versus prostate cancer-associated SPOP mutants and found a significant overlap between the differentially expressed genes and those with altered expression in the untreated conditions (Fig. 5a,b and Supplementary  Fig. 10a-c) . We identified 16 genes with altered expression across all conditions (untreated, 500 nM or 2 µM JQ1), including FOSL1, a reported target gene for BET proteins implicated in sensitivity to BET inhibitors 29 .FOSL1 mRNA and FOSLI protein levels were reduced in cells that overexpressed endometrial cancer-specific, as compared to prostate cancer-specific, SPOP mutants, in accordance with the observed changes in BET protein levels and the transcriptome analysis (Fig. 5c) . Notably, in human tumor tissues, FOSL1 mRNA and FOSLI protein levels were also decreased in individuals with endometrial cancer harboring mutated SPOP, with the lowest mRNA levels observed in individuals who harbored the SPOP mutants shown to have the strongest effects on BET protein levels and sensitivity to JQ1 in our study (Fig. 5d,e and Supplementary Fig. 7c) [30] [31] [32] [33] .
Next, we investigated whether changes in BET protein levels in response to SPOP mutants and JQ1 treatment might decrease FOSL1 transcription, as triple occupancy of BRD2, BRD3 and BRD4 has been reported at the FOSL1 promoter (Supplementary Fig. 10d) 24 . JQ1 treatment reduced FOSL1 expression levels in all conditions, whereas the relative expression levels remained the same between the different types of SPOP mutants (Fig. 5f) . Knockdown of individual BET proteins decreased FOSL1 mRNA levels in JQ1-resistant Ishikawa cells overexpressing the prostate cancer-specific SPOP-Y87C variant ( Fig. 4a and Supplementary Fig. 10e) . Moreover, FOSL1 depletion itself directly lowered resistance to JQ1 in this setting, indicating functional involvement of this gene downstream of changes in BET protein levels and SPOP mutants (Fig. 5g) . Taken together, these results suggest that BET protein level changes in response to SPOP mutants alter susceptibility to JQ1, at least in part, through transcriptional regulation of FOSL1.
JQ1 treatment blocks tumor growth in xenografts expressing endometrial cancer-specific SPOP mutants in vivo Finally, we investigated whether our results showing altered sensitivity to JQ1 in response to SPOP mutants could be validated in an in vivo setting. For this purpose, we focused on expression of endometrial cancer-associated SPOP mutants because patients receiving a beneficial response from BET inhibitors may be identified in this setting. Indeed, JQ1 efficiently blocked the growth of tumor xenograft models established from SPOP-mutant EN cells by reducing cell proliferation and inducing apoptosis, whereas Ishikawa-cell-derived tumors were largely resistant to JQ1 treatment (Fig. 6a-c) . In accordance with the in vitro data, forced expression of SPOP-E50K or SPOP-S80R sensitized Ishikawa cells to JQ1 in vivo (Fig. 6d,e ).
DISCUSSION
Recurrent missense mutations in SPOP-encoding a substrate receptor of a cullin-RING ubiquitin ligase-have been found in 5-10% of prostate and endometrial cancers in comprehensive genome sequencing studies [2] [3] [4] [5] [6] . Surprisingly, the specific genetic alterations show no overlap between these tumor types, even though they are confined to the same substrate-recognition domain. Although the prostate cancerassociated mutations have been shown more recently to stabilize protein substrates relevant to prostate tumorigenesis [8] [9] [10] [11] [12] , the therapeutic implications of both mutation types remain largely elusive.
Our study identifies the BET proteins (BRD2, BRD3 and BRD4) as bona fide SPOP substrates. Small-molecule inhibitors against this group of proteins are under clinical investigation in hematological and solid tumors because of the critical importance of these proteins in driving lineage-specific oncogenic transcriptional programs 18, 21, 23, 24 . We found that prostate cancer-associated SPOP mutations impair degradation of BET proteins, in line with the loss-of-function properties of these mutations reported previously 8, 9 , whereas endometrial cancer-associated SPOP mutations enhance BET protein degradation through a gain-of-function mechanism (Fig. 6f) . The precise structural basis through which endometrial cancer-associated SPOP mutations enhance binding and ubiquitination of BET proteins and other substrates (for example, DEK) remains to be further elucidated. The altered BET protein levels in the SPOP-mutant setting influence the transcription of established target genes, such as FOSL1 (ref. 29) , and thereby alter the susceptibility of cancer cells to BET inhibitors.
Of note in this regard, a recent report implicates enhanced FOSL1 activity as a mechanism of acquired resistance in ovarian cancer cells as well 34 . Overall, our established model extends the list of previously reported mechanisms that influence BET inhibitor sensitivity 27, 35, 36 .
BET inhibitors are currently under clinical development, and there is a critical need to identify patients who may respond to this treatment. Our preclinical study identifies SPOP mutations as a clinically detectable biomarker of BET inhibitor response. Thus, the detection of specific SPOP mutations may be used to select patients who may (endometrial cancer-associated SPOP mutations) or may not (prostate cancer-associated SPOP mutations) benefit from treatment with BET inhibitors.
More broadly, our results suggest a paradigm whereby mutations mapping to the same domain of a particular protein evoke opposing drug responses. Given the increasing use of cancer genome information in the clinical setting, caution may be needed when extrapolating therapeutic responses on the basis of similar mutations.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS

SILAC labeling and cell culture.
For SILAC experiments, human Ishikawa endometrial cancer cells were cultured in DMEM/F12 medium deficient in l-arginine and l-lysine and supplemented with 10% dialyzed FBS (Sigma-Aldrich), penicillin, streptomycin and l-glutamine (Invitrogen), and l-arginine (Arg-0) and l-lysine (Lys-0), l-arginine [ 13 C 6 ]HCl (Arg-6) and l-lysine-4,4,5,5-d 4 (Lys-4), or [ 13 C 6 , 15 N 4 ]HCl (Arg-10) and l-lysine [ 13 C 6 , 15 N 2 ]HCl (Lys-8) (Sigma-Aldrich) for 14 d (10 doublings). All media were supplemented with l-proline to prevent the conversion of arginine to proline 37 . Specifically, isogenic cell lines expressing vector control (C), wildtype SPOP (SPOP-WT) or mutants (MTs) were isotopically labeled with SILAC media and grouped into four experiments (Supplementary Fig. 1d) . Each experiment included a cell line with overexpression of SPOP-WT for cell line comparison within and across experiments. The labeling for this cell line was switched to rule out labeling artifacts in the first three experiments. Approximately 100 million cells per condition were washed twice with PBS, harvested and snap frozen.
K--GG profiling and proteome analysis by liquid chromatography mass spectrometry. Preparation of proteins for mass spectrometry analysis was completed as previously described 14 . Briefly, cell pellets were lysed in an ice-cold urea lysis buffer containing 8 M urea; 50 mM Tris-HCl, pH 8; 150 mM NaCl; 1 mM EDTA; 2 µg/ml aprotinin (Sigma-Aldrich); 10 mg/ml leupeptin (Roche Applied Science); 1 mM phenylmethylsulfonyl fluoride (PMSF); 50 µM PR-619; and 1 mM chloroacetamide. The lysate was cleared by centrifugation at 20,000g for 10 min. A bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific) was used to determine the protein concentration of each sample. Respective SILAC mixes were created by combining equal amount of protein per SILAC state. Proteins were reduced with 5 mM dithiothreitol (DTT) at room temperature (RT) and subsequently alkylated with 10 mM iodoacetamide at RT in the dark. Lysates were diluted 1:4 with 50 mM Tris-HCl, pH 8, and proteins were digested with sequencing-grade trypsin using an enzyme-to-substrate ratio of 1:50, overnight at 25 °C. Digestion reactions were quenched with trifluoroacetic acid (TFA), and the peptide solutions were cleared by centrifugation before desalting. Peptides were desalted using tC18 SepPak SPE cartridges (Waters) exactly as previously described 14 .
Peptides were fractionated offline by basic pH reverse-phase (bRP) chromatography, as previously described 14, 38 . Input for each bRP separation was equivalent to 30 mg of starting protein material (10 mg protein per SILAC state) for replicate. Briefly, dried peptides were reconstituted in bRP buffer A (5 mM ammonium formate (pH 10.0)/2% acetonitrile). A Zorbax 300 Extend-C18 column (9.4 × 250 mm, 300 Å, 5 µm; Agilent) was used for separation. Using the gradient and flow-rate settings previously described 14 , a total of 96 2-ml fractions were collected across the entirety of the bRP separation. For proteome analysis, 5% of each fraction was taken and combined in a noncontiguous manner such that every 24th fraction was combined to create 24 final fractions. For K-ε-GG analysis, the remainder of each fraction was combined in a noncontiguous manner such that every eighth fraction was combined to create eight final fractions. Pooled fractions were dried completely using vacuum centrifugation.
For enrichment of K-ε-GG peptides, anti-K-ε-GG antibody from the PTMScan Ubiquitin Remnant Motif (K-ε-GG) kit was used (Cell Signaling Technology, cat. no. 5562). Prior to enrichment, the antibody was cross-linked to protein A beads using dimethyl pimelimidate (DMP) 14 . Peptides were reconstituted in immunoaffinity purification (IAP) buffer, and enrichment was completed exactly as previously described 14 . Briefly, peptides were incubated with approximately 31 µg of anti-K-ε-GG antibody beads and incubated for 1 h at 4 °C with rotation. Beads were washed twice with 1.5 ml of ice-cold IAP buffer followed by three washes with ice-cold PBS. K-ε-GG peptides were eluted from the antibody with 2 × 50 µl of 0.15% trifluoroacetic acid (TFA). Peptides were desalted using StageTips. StageTips were conditioned by washing with 50 µl of 50% acetonitrile (MeCN) /0.1% formic acid (FA) followed by 2 × 50 µl of 0.1% FA. Peptides were then loaded on StageTips, washed twice with 50 µl of 0.1% FA and eluted with 50 µl of 50% MeCN/0.1% FA. Eluted peptides were dried completely using vacuum centrifugation.
Samples were reconstituted in 3% MeCN/0.1% FA. All samples were analyzed by nanoflow-ultra-performance liquid chromatography (UPLC)-higher-energy collisional dissociation (HCD)-MS/MS using a Q Exactive mass spectrometer (Thermo Fisher Scientific) coupled online to an Easy-nLC 1000 system (Proxeon). For K-ε-GG and proteome samples, 4/8 µl and 1/20 µl, respectively, were injected into the mass spectrometer. Samples were injected at a flow rate of 500 nl/min onto a PicoFrit column (360 µm (OD) × 75 µm (ID), 10-µm ID tip, 50-cm length (New Objective) self-packed with 24 cm of ReproSil-Pur 120-Å, 1.9-µm C18-AQ beads). The nanoflow column was heated to 50 °C using a column heater (Pheonix S&T). For liquid chromatography mass spectrometry (LC-MS/MS) analyses, the gradient and flow-rate settings were used as previously described 14 and the MS acquisition time used for each K-ε-GG and proteome sample was 120 min. The Q Exactive was operated by acquiring an MS1 scan (R = 70,000) followed by MS/MS scans (R = 17,500) on the 12 most abundant ions. An MS1 and MS2 ion target of 3 × 10 6 and 5 × 10 4 ions, respectively, was used for acquisition. A maximum ion time of 10 ms and 120 ms was used for the MS1 and MS2 scans, respectively. The isolation width was set to 2.5 m/z, the HCD collision energy was set to 25, the dynamic exclusion time was set to 20 s, and the peptide-match and isotope-exclusion functions were enabled. A second round of bRP fractionation, K-ε-GG and MS analysis was completed for experiments 3 and 4 (6 mg per SILAC state for experiment 3 and 10 mg per SILAC state for experiment 4).
Mass spectrometry data analysis. Data were processed using the MaxQuant (version 1.2.2.5) software package. The human UniProt database including 248 common laboratory contaminants was used for searching. The enzyme specificity was set to trypsin, the maximum number of missed cleavages was set to 2 for proteome data and 4 for K-ε-GG data, the precursor mass tolerance was set to 20 ppm for the first search, and the tolerance was set to 6 ppm for the main search. Carbamidomethylation of cysteines was searched as a fixed modification, and oxidation of methionines and N-terminal acetylation of proteins were searched as variable modifications.
For K-ε-GG data, addition of glycine-glycine to lysine was also searched as a variable modification. For identification, the minimum peptide length was set to 7, and the false discovery rate for peptide, protein and side identification was set to 1%. The filter-labeled amino acid and peptide quantification functions were enabled. For proteome data, normalized ratios were obtained from the "proteinGroups" table. For K-ε-GG data, normalized SILAC ratios were obtained from the "GlyGly(K)Sites" table.
For K-ε-GG and proteome data sets, reverse and contaminant hits were removed from the analysis. Proteins were included in the data set if they were identified and quantified by two or more razor peptides per unique peptide in each SILAC triple-labeled experiment. K-ε-GG peptides were included in the final data set if the corresponding protein was quantified in the proteome data.
To capture the ubiquitination changes associated with protein degradation, we normalized the K-ε-GG changes to their measured protein levels. The leading accession number was used to match the protein and K-ε-GG data. Quantitative, protein-normalized measurements were available for 17,239 K-ε-GG peptides. To assess and highlight which of the significantly deregulated K-ε-GG peptides were paralleled with opposing effects on total protein expression in the case of SPOP-MT versus SPOP-WT, protein-normalized SILAC ratios for K-ε-GG were multiplied by their corresponding protein-level ratio and also by −1 (Supplementary Fig. 2 and Supplementary Table 1 ).
Cell culture, transfection and infection. Ishikawa cells were purchased from Sigma; RL95-2, 22Rv1, MEF-962, VM-CUB1 and NCI-H508 cells were purchased from ATCC; EN cells were purchased from DSMZ; and HEC-151 cells were purchased from JCRB. AN3CA, HEC1A, HEC 1B, HEC116, SNG-II, EFE184 and KLE cells were kindly provided by E. Samartzis and K. Dedes (University Hospital Zurich). Ishikawa, RL95-2 and KLE cells were grown in F12/DMEM (Gibco); MEF-962, HEC-151, EN, HEC1A, HEC1B, AN3CA, HEC116 and SNG-II cells were grown in DMEM (Gibco); and 22Rv1 and EFE184 cells were grown in RPMI medium (Gibco); all were supplemented with 10% FBS (Gibco), 1% penicillin-streptomycin and l-glutamate. All cells were incubated at 37 °C and 5% CO 2 . Cells were routinely tested for mycoplasma contamination.
For transient transfection, cells were transfected with 50 nM siSPOP (Hs_SPOP_7, Qiagen), 50 nM siFOSL1 (Hs_FOSL1_1, Hs_FOSL1_2 and Hs_FOSL1_3, Qiagen) or siControl (Qiagen) using Fugene (Promega).
